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Gene–environment interactions underlie cancer susceptibility 
and progression. Yet, we still have limited knowledge of which 
environmental factors are important and how they function dur-
ing tumorigenesis. in this respect, the microbial communities 
that inhabit our gastrointestinal tract and other body sites have 
been unappreciated until recently. However, our microbiota are 
environmental factors that we are exposed to continuously, and 
human microbiome studies have revealed significant differences 
in the relative abundance of certain microbes in cancer cases 
compared with controls. To characterize the function of micro-
biota in carcinogenesis, mouse models of cancer have been treated 
with antibiotics. They have also been maintained in a germfree 
state or have been colonized with specific bacteria in specialized 
(gnotobiotic) facilities. These studies demonstrate that microbi-
ota can increase or decrease cancer susceptibility and progres-
sion by diverse mechanisms such as by modulating inflammation, 
influencing the genomic stability of host cells and producing 
metabolites that function as histone deacetylase inhibitors to 
epigenetically regulate host gene expression. One might consider 
microbiota as tractable environmental factors because they are 
highly quantifiable and relatively stable within an individual com-
pared with our exposures to external agents. At the same time, 
however, diet can modulate the composition of microbial com-
munities within our gut, and this supports the idea that probi-
otics and prebiotics can be effective chemoprevention strategies. 
The trajectory of where the current work is headed suggests that 
microbiota will continue to provide insight into the basic mecha-
nisms of carcinogenesis and that microbiota will also become tar-
gets for therapeutic intervention.
introduction
Cancer is a leading cause of death that is associated with tremendous 
social and economic burdens. In the USA, the number of cancer survi-
vors is projected to increase from 13.8 to 18.1 million over this decade 
and to cost $125 and $158 billion in healthcare expenses, respectively 
(1). In many developing countries, cancer incidence is increasing as a 
result of demographics (population aging) and the adoption of cancer-
associated lifestyle choices such as smoking, ‘westernized’ diets and 
physical inactivity (2). Increased exposure to known carcinogens or 
cancer suspect agents might also be a contributing factor, especially 
in countries with minimal regulatory oversight.
Similar to many other complex diseases, cancer susceptibility and 
progression are primarily influenced by gene–environment interactions. 
On the one hand, we have made considerable progress understanding 
the genetics and the molecular/cell biological mechanisms that underlie 
carcinogenesis (3). Most recently, our knowledge has been advanced by 
the advent of next-generation sequencing platforms to catalog recurrent 
mutations and epigenetic changes (via chromatin immunoprecipitation 
sequencing and bisulfite sequencing) that arise during tumorigenesis 
(4). Yet, on the other hand, we know relatively little about which envi-
ronmental factors influence cancer susceptibility and how they impact 
mechanisms of carcinogenesis. There have been some notable excep-
tions such as smoking and lung cancers as well as ultraviolet light 
exposure and melanomas, but this still remains an important challenge. 
Until recently, the microbiota that inhabit our body were unappreciated 
in this regard (unknown-unknowns in ‘Rumsfeldian speak’). However, 
these bacteria, archaea, eukaryotes (such as yeast and other fungi) and 
viruses (including bacteriophage) are environmental factors that we are 
continuously ‘exposed’ to, and recent work demonstrates that they can, 
in fact, influence carcinogenesis. Our microbiota might be considered 
known-unknowns at the present time because of our limited knowledge, 
but they are likely to become known-knowns considering the rapid pace 
of research in this area.
The human microbiome as revealed by metagenomic studies
The human body harbors ≥1014 microbial cells, which is ~10-fold 
greater than all of our somatic and germ cells combined. These micro-
biota and their collective genomes, referred to as the microbiome, are 
being characterized by metagenomics approaches that combine next-
generation sequencing platforms with the computational analysis and 
assembly of targeted (16S ribosomal RNA hypervariable region) and 
random (whole genome shotgun) DNA sequence reads (5,6). Based 
on these studies, we know that the composition of microbial commu-
nities varies across different anatomical sites (7,8). We also know that 
the vast majority of these microbes are bacteria that reside within the 
lumen of our gastrointestinal (GI) tract. The commensal and symbi-
otic bacteria that live within are gut are protected from predators such 
as nematode roundworms, and they also benefit from a consistent sup-
ply of nutrients provided by our carbohydrate-rich diets. In return, 
many of the symbiotic bacteria digest glycans into disaccharides and 
monosaccharides for the human host as well as for their own energy 
utilization. To carry out this function, the gut microbiome is highly 
enriched for genes involved in carbohydrate metabolism including 
≥115 families of glycoside hydrolases and ≥21 families of polysaccha-
ride lyases (9,10). In contrast, the human genome has relatively few 
genes that encode carbohydrate-metabolizing enzymes, presumably 
because mammals (and their genomes) coevolved with gut microbiota 
(and the gut microbiome). As a result of this symbiotic relationship, 
gut microbiota are believed to improve our ability to absorb nutrients 
and extract calories from our diets (11,12).
Although microbial populations are conserved at higher taxo-
nomic levels (13), metagenomic studies have documented substantial 
variation at the genus and species levels among human individuals 
(8,14). This interindividual variation is due to both host genetics and 
environmental factors. In support of host genetics, a genome-wide 
association study combined with 16S ribosomal RNA metagenomics 
data on a large (n = 645) panel of mouse lines identified a number of 
quantitative trait loci that influence the relative abundance of specific 
microbial taxa (15). In support of environmental factors, there is also 
microbial variation within a human individual over their lifespan (par-
ticularly from infancy to adolescence) and in response to diet, stress, 
household pets, antibiotics, chemotherapeutics and exposure to prob-
ably many other agents (16–23).
Human disease susceptibility is primarily influenced by gene–envi-
ronment interactions, and the microbiome is now believed to be an 
important factor. Indeed, microbiome differences are evident between 
cases and controls for a growing list of human diseases including 
Crohn’s disease, type-2 diabetes, autism and chronic allergies (24–26). 
The microbial imbalances associated with these complex disease states, 
Abbreviations: DCA, deoxycholic acid; GI, gastrointestinal; IL, interleukin; 
pks, polyketide synthase; TLR, toll-like receptor.
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which is referred to as dysbiosis, usually involves shifts in the rela-
tive abundance of many commensal microbes rather than a simple 
‘one microbe-one disease’ relationship that can exist for certain path-
ogens such as human immunodeficiency virus and acquired immu-
nodeficiency syndrome or Helicobacter pylori and gastric ulcers. 
This dichotomy is analogous to the difference in genetic complexity 
between quantitative (polygenic) and Mendelian (monogenic) traits. 
In the context of gene–environment interactions, it is tempting to spec-
ulate that single-nucleotide polymorphisms, mutations or epigenetic 
perturbations of human disease genes (including tumor suppressors 
and proto-oncogenes) might influence an individual’s microbiome. 
This would represent a novel biological function and provide mecha-
nistic insight or have translational potential for the diagnosis and treat-
ment of the disease state. One candidate is the Dectin-1 gene because 
a human single-nucleotide polymorphism is associated with a severe 
form of ulcerative colits and the corresponding knockout mice exhibit 
increased sensitivity to dextran sodium sulfate-induced colitis associ-
ated with differences in indigenous gut fungi (27).
Differences in microbiota are also associated with several types 
of cancer (Table I), and the advent of microbiome sequencing pro-
jects means that more types of cancer will undoubtedly be added to 
this list in the near future. This might be particularly true for certain 
carcinomas because the bacterial density is highest near mucous 
membranes of gut, lung and urogenital tract epithelia. Mucous 
membranes form barriers between our bodies’ tissues and microbial 
communities and also have important immunoregulatory functions 
(28). The mucosa is compromised in certain disease states such as 
Crohn’s disease, and these permeability defects arise because of 
perturbed tight junctions. Furthermore, some components of tight 
junctions such as E-cadherin and β-catenin are dysregulated in epi-
thelial tumors (28). It should be mentioned that our knowledge of 
mucosal-associated microbial communities is more limited than 
might be expected. This is because most gut microbiome studies 
have been performed on stool samples since they can be readily 
obtained in a non-invasive manner. However, the composition of 
fecal-associated bacterial communities in stool samples is distinct 
from mucosal-associated communities obtained during colonosco-
pies (29–31).
Most of the observed microbiome differences that have been iden-
tified thus far involve many changes in the microbiota where any one 
alteration may have a subtle or modest effect, whereas the combined 
effect in aggregate is more robust. In addition, as with other diseases, 
there are pathogens capable of driving ‘one microbe-one disease’ 
neoplasms such as human papillomavirus for cervical cancer and 
H. pylori for gastric cancer (Table I). Tumor-associated viruses are 
noteworthy because of their previous role in the discovery of cellular 
proto-oncogenes. Another analogy is that the difference in microbial 
complexity between these scenarios (in Table II) is similar to the dif-
ference in genetic complexity between sporadic and familial cancers. 
It is also possible that both situations coexist during tumorigenesis. 
For example, two recent studies performed metagenomic sequencing 
on a combined total of 20 pairs of colorectal tumors matched with 
normal adjacent colonic tissues from the same individuals (32,33). 
Members of two dominant phyla associated with healthy individuals, 
Bacteroidetes and Firmicutes, were underrepresented in the tumors, 
whereas an invasive anaerobe (Fusobacterium nuculeatum) previ-
ously associated with periodontitis and appendicitis was significantly 
overrepresented in the tumors. Both groups confirmed their findings 
on a larger cohort of paired specimen (n = 95 and n = 99) using PCR 
analyses (32,33). Despite these consistent differences; however, the 
overall microbial communities of a tumor and matched non-cancer-
ous colon from one individual were more similar to each other than 
were tumors or non-affected colon samples from different individu-
als. This supports the idea that the microbiome will be an important 
factor in personalized medicine.
Functional studies using gnotobiotic mouse models
A limitation of metagenomic studies is that they are correlative so it 
is difficult or impossible to know whether a particular microbiome 
difference is a cause or a consequence of a corresponding disease 
state. To establish cause-and-effect relationships, it is necessary to 
manipulate the microbiota in a rigorously controlled manner. For this 
reason, experiments with gnotobiotic mouse models are crucial, and 
this is why these models will likely play a more prominent role in 
future biomedical research. Maintained in a specialized gnotobiotic 
facility where sterility is maintained, laboratory mice can be raised in 
a completely germfree state (i.e. without any microbiota) if their diets 
are autoclaved and fortified with certain essential vitamins that are 
normally synthesized by microbiota (34). A number of studies have 
compared germfree mice to controls that are genetically identical but 
that have been colonized with a complete, albeit undefined, micro-
biota (referred to as conventionalized or conventionally derived) or 
that always have been maintained in a specific pathogen-free facility 
(referred to as conventionally raised). Compared with conventional-
ized or conventionally derived or conventionally raised controls, ger-
mfree mice consume more food, yet they are leaner with ~35% less 
adipose tissue (35). Germfree mice exhibit other metabolic anoma-
lies (e.g. hypoglycemia and decreased levels of insulin and glycogen) 
and are resistant to obesity when provided a high-fat diet (35). These 
experiments support the metagenomic data suggesting that the gut 
microbiome increases calorie extraction of the host. This principle 
is exploited by the agricultural industry, which uses subtherapeutic 
Table i. Microbiota changes that have been observed in human cancer cases 
Cancer type Sampling site Microbiome changes in cases compared  
with controls
References
Oral squamous cell carcinoma Saliva Incr: Capnocytophaga gingivalis, C. ochracea, 
Eubacterium sabureum, Leptotrichia buccalis, 
Streptococcus mitis
(100–102)
Barrett’s esophagus and esophageal cancer Saliva, biopsied tissue Incr: Campylobacter consisus, C. rectus, 
Treponema denticola, S. anginosus, S. mitis; 
Decr: Helicobacter pylori
(101,103–105)
Pancreatic cancer Saliva Incr: n = 31 including S. mitis and Neisseria 
elongata; Decr: n = 25
(101,106)
Gall bladder cancer Bile culture Incr: Salmonella typhi, S. paratyphi; bile 
usually free from bacteria but infected in cases
(101,107)
Colorectal cancer Feces, biopsied tissue Incr: S. bovis, Streptococcus spp., Escherichia 
coli, Fusobacterium nucleatum, Clostridium, 
Bacteroides; Decr: Lactobacillus, butyrate- 
producing bacteria (including Roseburia 
and Fecalibacterium), Microbacterium, 
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doses of antibiotics to alter the microbiome in a manner that pro-
motes the growth of farm animals. This effect has been recapitulated 
in mice where subtherapeutic doses resulted in increased adiposity 
without affecting caloric intake or hormones that regulate satiety 
(36). Furthermore, specific microbiome changes were documented in 
mice, and the juvenile stage of postnatal development was a sensitive 
developmental window because adiposity was increased even when 
early-life exposures were followed by a curtailment of the antibiotic 
regimen. This may have implications in the obesity epidemic consid-
ering the pervasive use of antibiotics and the fact that low doses of 
antibiotics can be detected in drinking water.
Germfree mice have also been used to demonstrate that microbiota 
play an important role regulating our immune system and inflam-
matory responses (37). For example, interleukin (IL)-10 is a potent, 
immunosuppressive cytokine, and IL-10 knockout mice exhibit a 
colitis phenotype that is rescued by maintaining them in germfree 
state (38). This observation suggests that a primary function of IL-10 
is to prevent an inappropriate inflammatory response against com-
mensal gut microbiota. Similarly, transforming growth factor-β1 
knockout mice exhibit colorectal inflammation and cancer, and both 
of these phenotypes are rescued on a germfree background (39). 
These results are consistent with the observation that germfree mice 
have fewer proinflammatory T helper 17 cells in the lamina propria 
of their gut than specific pathogen-free controls (40,41). The role 
of microbiota in both cellular energetics and the immune response/
inflammation is relevant to cancer because these functional catego-
ries are recognized as hallmarks of cancer (3). In fact, it is tempting 
to speculate that microbiota may be added as a hallmark in the future.
Germfree mice can be colonized with specific microbial communi-
ties to assess their role in host physiology. For example, a number of 
studies have demonstrated that differences in microbial composition 
can influence malnutrition susceptibility at one extreme and obesity 
at the other extreme without affecting food intake (12,42–44). Some 
of these and other studies have used ‘humanized mice’, which are 
colonized with microbiota isolated from human cases versus con-
trols, to interrogate the function of human microbes. Germfree mice 
can also be monoassociated or polyassociated with a small number 
of microbes. This reductionist approach makes it possible to assign 
function to a specific microbe(s) and sometimes a specific microbial 
gene or metabolite. These types of studies are beginning to provide 
mechanistic insight into how microbes promote or inhibit a variety 
of disease states including cancer as exemplified below.
Microbiota, inflammation and genomic instability
As mentioned above, inflammation is an important factor in carcino-
genesis. For example, colitis patients have a 10-fold increased risk of 
colorectal cancer (45), and non-steroidal anti-inflammatory drugs such 
as aspirin have been effective for cancer prevention and as adjuvant 
therapies (46,47). A recent study demonstrated that members of the 
Enterobacteriaceae family are upregulated by up to ≥100-fold in the 
colons of IL-10 knockout mice with colitis compared with wild-type 
control mice without colitis (48). Monoassociation of IL-10 knockout 
mice with two of these commensal bacteria (strains of Escherichia 
coli and Enterococcus faecalis) indicated that each one was competent 
to induce colitis. However, only one of the two, the E. coli strain but 
not E. faecalis, was capable of driving colorectal cancer in the same 
mice after they were treated with the procarcinogen azoxymethane. 
These results suggest that inflammation may have been necessary but 
was not sufficient for carcinogenesis in this model. Therefore, the next 
objective was to identify other bacterial-triggered events that contrib-
ute. Further analysis revealed that the E.  coli strain harbors a ~54 
kb polyketide synthases (pks) pathogenicity island, which encodes 
enzymes that synthesize a genotoxin named colibactin, that is lacking 
in the E. faecalis strain. To demonstrate that colibactin is function-
ally important for cancer, IL-10 knockout mice were monoassociated 
with an isogenic strain of E. coli in which pks had been deleted. The 
Δpks strain colonized mice and stimulated inflammation as well as the 
+pks strain but was unable to induce tumor formation. Consistent with 
colibactin being a genotoxin, the +pks E. coli strain was associated 
with DNA damage in colorectal tumors based on γH2AX as a marker, 
whereas the Δpks strain did not induce DNA damage. These find-
ings have human relevance because the same study reported that +pks 
E. coli strains are more highly enriched in patients with inflammatory 
bowel disease and colorectal cancer than controls (48).
A functional link between bacterial-mediated inflammation and 
DNA damage was also revealed by a study of RAG-2 knockout mice 
infected with H. hepaticus in a specific pathogen-free facility (49). 
Infiltration of activated macrophages and neutrophils resulted in 
increased production of cytokines and chemokines as well as nitric 
oxide, superoxide and a number of reactive species that led to DNA 
and RNA damage products and culminated in colorectal cancer.
DNA damage and cancer risk are likely to be affected by food–
microbiota interactions more often than microbiota in isolation (50). 
This is particularly true for red meat, which is a significant risk factor 
for several types of cancer (51). Heterocyclic amines from charred 
meat are fermented by colonic bacteria, and some of the metabo-
lites are electrophilic and believed to damage DNA and contribute 
to colorectal cancer (52). Red meat and other high-protein foods are 
also metabolized by sulfate-reducing gut bacteria to yield hydrogen 
sulfide, which is also believed to contribute to cancer, particularly 
when DNA repair mechanisms are perturbed (50,52).
Based on epidemiology studies, obesity is a significant risk factor 
for several common types of cancer (53), and the worldwide obesity 
epidemic portends an increased incidence of cancer. Numerous fac-
tors including inflammation contribute to obesity-associated cancer 
(53,54), and evidence has recently emerged that bacterial metabolites 
can play a role. In one such study, tumorigenesis was initiated in mice 
with the carcinogen 7,12-dimethylbenz(a)anthracene, which induces 
Ras mutations at a high frequency (55). Obese mice that were either 
leptin deficient (ob/ob) or that were wild-type but provided a high-
fat diet developed hepatocellular carcinoma, whereas lean mice that 
were genetically wild-type and provided a standard diet did not. The 
obese mice had increased representation of bacteria in the Firmicutes 
phylum, which is consistent with previous studies and their proposed 
role in increasing calorie extraction of the host. Bacteria in cluster IX 
of the genus Clostridium were particularly overrepresented, and they 
are able to convert primary bile acids into a secondary bile acid named 
deoxycholic acid (DCA). DCA is a carcinogen that can cause DNA 
damage via the production of free radicals, and it has been implicated 
in liver and colorectal cancers. The obese mice did, in fact, have higher 
serum levels of DCA, which made it a plausible candidate. To dem-
onstrate that Clostridium and DCA are functionally important, a cou-
ple of experiments were performed. First, when 7,12-dimethylbenz(a)
anthracene-treated obese mice were treated with a couple different 
antibiotic regimens, serum DCA levels and the liver cancer phenotype 
were significantly attenuated. This was the case for vancomycin, which 
preferentially kills Gram-positive bacteria including the Clostridium 
Table ii. Single microbes that can drive human cancer 
Microbe Cancer type(s)
Helicobacter pylori Gastric adenocarcinoma, gastric 
lymphoma, esophageal adenocarcinoma
Human papillomavirus  
(HPV)
Anogenital carcinomas, oropharyngeal 
carcinoma




Hepatitis B virus Hepatocellular carcinoma
Hepatitis C virus Hepatocellular carcinoma, lymphomas
Human T-cell lymphotropic 
virus type 1 (HTLV-1)
Adult T-cell leukemia/lymphoma
Human herpesvirus 8 
(HHV-8)
Kaposi’s sarcoma
Adapted from reference (94).
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species that had been overrepresented. Second, DCA production was 
diminished by two different strategies without the use of antibiotics 
(by either decreasing 7α-dehydroxylation activity with difructose 
anhydride III or stimulating bile acid secretion with ursodeoxycholic 
acid), and this also attenuated the tumor phenotype.
Other inflammatory mechanisms
Microbial-induced inflammation can also contribute to cancer by 
stimulating the production of cytokines and chemokines that promote 
cell proliferation and/or inhibit apoptosis. In another mouse model 
of hepatocellular carcinoma, where diethylnitrosoamine and CCl4 are 
used to induce chronic liver injury, intestinal microbiota were shown 
to be dispensable for tumor initiation but important for tumor promo-
tion (56). This was demonstrated by significantly decreasing the liver 
tumor burden when the mice were treated with antibiotics or when 
they were analyzed on a germfree background. Mice with a knockout 
of toll-like receptor 4 (TLR4), which is a cell surface receptor that 
senses bacterial lipopolysaccharides, exhibited a similar decrease in 
tumor burden. In wild-type mice that were treated with diethylnitro-
soamine and CCl4, TLR4 signaling led to increased expression of the 
hepatomitogen epiregulin, which may have mediated some of the pro-
liferative and antiapoptotic effects that were observed in the tumors. 
However, TLRs signals through MyD88 and nuclear factor-κB to 
regulate the expression of many cytokines and other genes.
The TLR-signaling pathway is crucial for the innate immune sys-
tem, and, in turn, this can modulate microbial composition and other 
host functions. TLR5 and TLR2 serve as examples. TLR5 knockout 
mice exhibit signs of metabolic syndrome such as hyperphagia, insulin 
resistance and increased adiposity, and this phenotype is exacerbated 
by a high-fat diet as expected (57). The lack of a similar phenotype in 
MyD88 knockout mice suggests that a non-canonical signaling path-
way might be utilized. TLR5 is highly expressed in the intestine and 
recognizes bacterial flagellin, and the metabolic syndrome phenotype 
was associated with 116 microbiota changes at the species level (i.e. 
phylotypes) without significant changes at the overall phylum level. To 
demonstrate that these microbiota changes are significant, antibiotics 
were used to rescue the phenotype. More importantly, when microbiota 
from TLR5 knockout mice were transplanted into wild-type recipients 
that had been germfree, certain features of metabolic syndrome were 
recapitulated. This experiment demonstrates that microbiota can cause 
an altered metabolic state rather than simply being a consequence. In 
the case of TLR2, it is expressed on the surface of Treg cells and rec-
ognizes polysaccharide A from Bacteroides fragilis (58). Activation 
of the TLR2 pathway in these cells promotes immunologic tolerance 
and allows this commensal bacterium to colonize the gut rather than 
being eliminated. In contrast, B. fragilis lacking polysaccharide A does 
not receive immunological tolerance and is eliminated via the T helper 
17 response. This type of mechanism may enable the immune system 
to discriminate between commensal bacteria and pathogens and to 
respond accordingly. One possible complication regarding these experi-
ments is that there is evidence that differences in microbial composition 
are not apparent immediately following intercrosses but require TLR+/+ 
and TLR−/− mice to be bred separately for multiple generations (59,60).
Immune cells in the tumor microenvironment can respond to 
lipopolysaccharide, flagellin and other bacterial products by producing 
a battery of cytokines such as IL-23, IL-17 and IL-22BP that modulate 
tumorigenesis in the colon and other tissues (28,61,62). Furthermore, 
there is a two-way flow of information as human metabolites can 
influence microbial populations. For example, in response to intes-
tinal inflammation, mammalian cells produce nitrate, S-oxides and 
N-oxides, which can be used by a subset of microbiota (facultative 
anaerobes but not obligate anaerobes) as electron acceptors for anaero-
bic respiration (63). This leads to a growth advantage of facultative 
anaerobes and is due to nitrate respiration because an E. coli strain that 
had several nitrate reductase genes inactivated was outcompeted by an 
isogenic, wild-type strain. The facultative anaerobes that had a growth 
advantage were using host-derived nitrate based on the effect being 
negated in mice with a knockout of inducible nitric oxide synthase.
Probiotics and prebiotics in cancer prevention
Some of the experiments described above used antibiotics to 
decrease the tumor burden in mouse models. However, antibiot-
ics are not good candidates for chemotherapy or chemotherapeu-
tic adjuvants in the clinic. Not only would this approach make the 
problem of antibiotic-resistant bacterial strains even worse, but this 
would also kill many commensal bacteria including some that likely 
promote homeostasis and protect against carcinogenesis. It has been 
proposed that increased antibiotics usage is altering our microbiota 
and contributing to the increased incidence of obesity, inflamma-
tory bowel disease, allergies and asthma (64), and this may also 
apply to certain cancers. In fact, as H. pylori has been eradicated 
to a large extent in western countries, gastric cancer has decreased 
but esophageal cancer has become more common. One possibility is 
that H. pylori can alter stomach pH and acid reflux in a manner that 
protects against Barrett’s esophagus and esophageal cancer (64).
Instead of using antibiotics to kill bacteria indiscriminately, it 
would be better to take steps that restore a beneficial microbial 
composition. This is the basis for fecal microbiota transplantations 
that are effective for the treatment of diarrhea in people with severe 
Clostridium difficile infections, which usually arise because antibiot-
ics eliminated commensal bacteria that are capable of displacing or 
suppressing C. difficile. To make these transplantations more uniform, 
pathogen free and aesthetically appealing, it should be possible to 
inoculate people with a beneficial mixture of gut bacteria. As a proof 
of principle, a recent study transplanted a culture of six phylogeneti-
cally diverse gut microbes into mice with C. difficile infections, and 
this restored a normal microbial community, displaced the C. difficile 
and resolved the disease as well as homogenized feces (65).
Probiotics and prebiotics are more common ways to establish and 
maintain healthy microbiomes (66). Probiotics refers to live microorgan-
isms present in foods or dietary supplements that confer a health benefit. 
Lactobacilli in yogurt is the best known example, but Streptococci and 
Bifidobacteria in cheeses or other foods and drinks are also common. 
One well-known benefit of Lactobacilli in yogurt is improved diges-
tion of dairy products in individuals who are lactose intolerant. This 
allows some people to increase their intake of calcium and is notewor-
thy because the prevalence of lactose intolerance ranges from 5 to 15% 
in northern European countries and the USA to >50% in African and 
Asian countries (66). The beneficial effect is due to live bacteria, which 
provide β-galactosidase (lactase) activity, because heated or pasteurized 
yogurt is not effective (67,68). It should also be possible to improve pro-
biotics by supplementing foods with bacteria engineered to either have 
stronger beneficial effects or to more stably colonize the human GI tract. 
For example, a strain of Lactobacillus acidophilus with a deletion in 
the phosphoglycerol transferase gene is unable to synthesize lipoteichoic 
acid, and oral administration of this bacterium to ApcΔfloxed mice resulted 
in the regression of already established colonic polyps (69). Strains of L. 
casei and Lactococcus lactis have been engineered to produce a protein 
called elafin that diminished inflammation in a mouse model of colitis 
(70). When these bacteria were added to inflamed epithelial cells from 
human colitis patients ex vivo, they attenuated cytokine production and 
cell permeability. A final example is a strain of L. gasseri, which was 
engineered to overexpress the antioxidant superoxide dismutase and 
decreased colitis in IL-10 knockout mice (71).
Prebiotics refers to indigestible food ingredients that selectively stim-
ulate the growth and/or activity of certain gut microbiota that confer a 
health benefit. Common prebiotics include dietary fiber sources such as 
inulin that promote the growth of Bifidobacteria. A number of prebiot-
ics have been implicated in cancer prevention (72). Dietary polyphenols 
are among the most studied prebiotics. They include flavonoids, phe-
nolic acids, and lignins present in tea, wine, fruits, nuts, and vegetables. 
Ellagic acid is a polyphenol present in certain berries and nuts that is an 
antioxidant with cancer-preventive properties. Ellagic acid is metabo-
lized by colonic microbiota into urolithins that have proestrogenic and 
antiestrogenic activities in a context-dependent manner (73). Urolithins 
can also downregulate COX-2-mediated inflammation so the anticancer 
effects might involve multiple pathways (74).
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Another polyphenol is daidzein, which is a soy isoflavone metab-
olized by gut microbiota into equol (75). Equol can be detected in 
only 30–40% of individuals, and, although the reason for this is not 
understood, it could be due, in part, to the relative abundance of spe-
cific bacteria (72). The ability to produce equol is positively corre-
lated with sulfate-reducing bacteria and negatively correlated with 
C. coccoides and Eubacterium rectale (76). Some epidemiological 
studies have reported correlations between equol or equol-producing 
bacteria and diminished breast cancer risk in women and diminished 
prostate cancer risk in men. However, these correlations have been 
observed in Asian populations but not European populations (77). It 
is not clear whether these ethnic disparities are due to differences in 
genetics, microbiota or diet (e.g. soy consumption), and more work 
will be required to strengthen the link between equol and cancer pre-
vention. Generally speaking, based on situations like this, it would 
be advantageous to combine prospective epidemiology studies with 
genome-wide association studies and microbiome studies. This kind 
of integrated approach might allow a combination of factors to be 
identified that have a significant and reproducible effect regarding diet 
and chemoprevention. In addition, it would be cost effective and use-
ful to assess relatively short-term probiotic and prebiotic regimens 
by performing metabolomics or analyzing cancer-related biomarkers 
as surrogates and then use this information to direct more expensive, 
longer term chemoprevention or intervention trials.
Dietary fiber, gut microbiota and butyrate in colorectal  
cancer prevention
Fiber is a probiotic fermented by bacteria into short-chain fatty acids that 
can reach very high (mM) levels in the lumen of the colon (78). Butyrate 
is one of the most abundant of these short-chain fatty acids and is selec-
tively transported into the colonic epithelium. Unlike most cells in the 
body, which utilize glucose as their primary energy source, colonocytes 
rely on butyrate for ~70% of their energy needs (79,80). As a fatty acid, 
butyrate is an oxidative energy source that undergoes β-oxidation fol-
lowed by the trichloroacetic acid cycle inside of mitochondria. Because 
virtually all butyrate is derived from bacteria rather than directly from 
food, colonocytes from germfree mice have suboptimal energetics 
including ~50% lower levels of adenosine triphosphate and consequently 
undergo autophagy (81,82). To demonstrate that these metabolic defects 
are due to butyrate deficiency, when butyrate is added to germfree colo-
nocytes ex vivo, normal metabolic parameters are restored (81).
Fiber has been implicated in the prevention of colorectal cancer, and 
butyrate is one of the most plausible tumor-suppressive molecules. This 
is consistent with microbiome studies that have reported fewer butyrate-
producing bacteria in colorectal cancer cases than controls (83–87). 
Although butyrate promotes the growth of normal colonocytes, it inhib-
its the growth of colorectal cancer cell lines via decreased cell prolifera-
tion coupled with increased apoptosis and/or cell differentiation. The 
observation that butyrate has opposing effects on normal versus cancer-
ous colonocytes has been referred to as the butyrate paradox (88), and 
recent work has shown that this is due to the Warburg effect (89). Unlike 
normal colonocytes, cancerous colonocytes undergo the Warburg effect 
by upregulating glucose intake (via increased GLUT expression) and 
aerobic glycolysis with a concomitant decrease in oxidative metabo-
lism. As a result, less butyrate is metabolized in the mitochondria of 
cancer cells and more of it accumulates in the nucleus where it acts as 
an endogenous histone deacetylase inhibitor (90). Butyrate increases 
histone acetylation and transcription of cancer-related genes important 
for cell proliferation (e.g. p21), apoptosis (e.g. BAX, BAK, FAS) and 
cell differentiation (e.g. mucins).
Butyrate has potent anti-inflammatory properties so it probably 
also has tumor-suppressive properties that are not cancer cell autono-
mous. For example, butyrate ameliorates the inflammation associated 
with colitis in both rodent models and human patients (91). Some of 
these effects are probably due to histone deacetylase inhibition and 
epigenetic regulation of gene expression, but there is also evidence 
that it can signal though G-protein-coupled receptors to stimulate the 
expansion of Treg cells (92).
Other metabolomic properties of the microbiome in cancer
The metabolic capacity of the microbiome is so prodigious that it 
has been referred to as our second liver, and it is known to influence 
human health and disease susceptibility in a variety of ways (93). This 
applies to cancer, ranging from cancer prevention at the earliest stages 
of disease to how individuals respond to chemotherapy at the latest 
stages of disease. Regarding the earliest stages of cancer, the role of 
microbiota in promoting or inhibiting tumor initiation and progres-
sion is not restricted to direct effects on tumorigenesis. For exam-
ple, gut microbiota play an important role in estrogen metabolism, 
and higher estrogen levels are a major risk factor for endometrial and 
breast cancers (94). This is dependent on bioactive food components 
as discussed above for the connection between ellagic acid, bacterial 
urolithins and their proestrogenic and antiestrogenic activities (73).
Regarding later stages of cancer, camptothecin is a topoisomer-
ase I  inhibitor commonly used for chemotherapy, and microbiota 
influence the occurrence of diarrhea as an adverse side effect (95). 
Camptothecin-11 is a prodrug that is converted to SN-38 as the active 
chemotherapeutic. In the liver, SN-38 is inactivated by glucuronosyl-
transferases, and inactive SN-38G is excreted via the bile ducts into 
the GI tract. However, commensal bacteria in the intestines express 
glucuronidases that remove the glucuronide group to reactivate 
SN-38, which harms rapidly dividing intestinal epithelial cells and 
causes diarrhea (95). Antibiotics were evaluated as a treatment option 
but not pursued because the indiscriminate killing of bacteria results 
in C. difficile infections and other events that would have been par-
ticularly deleterious to cancer patients. As an alternative approach, 
pharmacologic inhibitors of bacterial β-glucuronidases were identi-
fied that prevent reactivation of SN-38, and oral administration of 
these inhibitors to camptothecin-11-treated mice protected them from 
diarrhea without killing bacteria or harming mammalian cells (95). 
This and other recent studies establish a precedent for drug discovery 
where the activity of bacterial targets are modulated to improve the 
outcome of disease or to minimize side effects (96–98).
Future directions
Metagenomics will continue to catalog microbial communities, but this 
approach does have a couple of limitations. First, metagenomics does 
not evaluate microbial gene expression, and it is the composite gene 
expression profiles of microbial communities that will determine micro-
biome function. To address this issue, it is now possible to move from 
metagenomics to metatranscriptomics by performing RNA-seq on sam-
ples from different anatomical sites (99). In the future, metatranscriptom-
ics projects will provide insight into how diet and other environmental 
factors influence the expression of each gene within the microbiome. 
Metatranscriptomics will also be incorporated into case–control stud-
ies to identify microbial genes and genetic pathways that are altered in 
cancer and other disease states. Second, there is considerable functional 
redundancy between bacterial species that is commensurate with taxo-
nomic relationships (7). Therefore, the microbial diversity or differences 
identified in microbiome studies is not equivalent to functional diversity 
or differences. For this reason, the metabolic capacity of different bac-
terial communities will need to be characterized in an accurate, high-
throughput and cost-effective manner. The microbial meta-metabolome 
is determined, in part, by the relative abundance of microbiota (as deter-
mined by metagenomics) and their corresponding gene expression pro-
files (as determined by metatranscriptomics), and this will bring us a step 
closer to understanding the translational implications for human health. 
However, the metatranscriptome and meta-metabolome are probably 
influenced by diet and other factors to an even greater extent than the 
metagenome, and this will increase variability and present challenges.
We have not yet developed culture conditions that support the 
growth of most microbes that inhabit the human body, particularly 
anaerobic bacteria that reside deep within our GI tract. This has 
not prevented us from using metagenomics to characterize micro-
bial populations and to identify microbiome differences between 
individuals with certain diseases including cancer compared with 
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controls. It is important that these studies continue and that they 
be integrated with epidemiology studies (especially with respect 
to diet), genome-wide association studies and metabolomics. 
However, it will become increasingly important to culture specific 
bacteria so they can be analyzed in gnotobiotic mouse models. 
Genetically engineered mouse models of cancer and other diseases 
are known to be influenced by genetic background, and it will be 
important to learn about the role of microbiota in modifying these 
phenotypes. The ability to culture and manipulate specific bacte-
ria and introduce them into gnotobiotic mouse models will allow 
us to move from correlation to causation and will provide insight 
into molecular mechanisms, which may lead to improved probi-
otic/prebiotic strategies of disease prevention as well as therapeutic 
interventions.
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